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Abstract
Background: The prevalence of thyroid autoimmunity
and subclinical primary hypothyroidism in persons
with chronic kidney disease (CKD) not requiring
chronic dialysis is not well defined.
Methods: We studied 1000 consecutive adult outpa-
tients who were referred by their general practitioner
for blood testing over the last 2 years. We excluded
those with abnormal serum free thyroxine (FT4) levels
(ns85). No participants required chronic renal repla-
cement therapy. Thyroid autoimmunity was defined
as increased concentrations of serum anti-thyroid
antibodies. Subclinical primary hypothyroidism was
defined as a serum thyrotropin (TSH) concentration
)4 mIU/L. CKD was defined as an estimated glome-
rular filtration rate (eGFR) -60 mL/min/1.73 m2.
Results: Overall, 53 (5.8%) subjects had eGFR
-60 mL/min/1.73 m2. Of these, 98 (10.7%) had sub-
clinical hypothyroidism, and 213 (23.3%) subjects had
increased anti-thyroid antibodies. Approximately 26%
and 34% of those with eGFR -60 mL/min/1.73 m2 had
laboratory evidence of subclinical hypothyroidism or
thyroid autoimmunity, respectively. In subgroup anal-
ysis stratified by TSH and thyroid autoimmunity,
decreasing eGFR values appeared to be more strong-
ly related with the increase in TSH rather than anti-
thyroid antibodies.
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Conclusions: Thyroid autoimmunity and subclinical
primary hypothyroidism are highly prevalent in per-
sons with CKD not requiring chronic dialysis.
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Introduction
There is extensive linkage between the kidneys and
thyroid function in the embryonic stage. This linkage
becomes more evident in clinically overt hyperthy-
roidism and hypothyroidism. These conditions lead to
hemodynamic and vascular changes in the kidney, as
well as to changes in the structure and function of the
tubules and glomerulus (1). An increased prevalence
of goiter and thyroid gland volume has been reported
in patients with chronic kidney disease (CKD) (2, 3). It
has been suggested that clinically overt hypothyroid-
ism may be more common in patients with CKD com-
pared with the general population (1).
Interestingly, CKD was found to be associated with
a greater prevalence of clinical and subclinical pri-
mary hypothyroidism among participants of the Third
National Health and Nutrition Examination Survey (4).
Recently, we extended these findings in a large non-
US cohort of outpatients by showing that the preva-
lence of subclinical hypothyroidism increases as
estimated glomerular filtration rate (eGFR) decreases
(5). These findings may have important clinical impli-
cations because subclinical primary hypothyroidism,
independent of its specific etiology, is associated with
an increased risk of cardiovascular events (6–8).
At present, there is no information about the prev-
alence of subclinical primary hypothyroidism caused
by chronic autoimmune thyroiditis, the most common
cause of primary hypothyroidism (9), in persons with
CKD who do not require maintenance dialysis.
The purpose of this study was to investigate the
prevalence of thyroid autoimmunity and subclinical
primary hypothyroidism at different levels of kidney
function in a large sample of unselected adult
outpatients.
Materials and methods
A cross-sectional analysis of the database of the Laboratory
Information System of the Clinical Chemistry Laboratory at
the Verona University Hospital was performed. We retrieved
serum creatinine and thyroid function test results from all
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adult outpatients, 18 years of age or older (ns1000), who
were consecutively referred for testing by general practition-
ers over the last 2 years (from April 2007 to April 2009). If a
subject had more than one blood test ordered over the 2
years, only the first result was included in the analysis. For
this study, participants who had abnormal serum free thy-
roxine (FT4) concentrations (ns85) were excluded. No par-
ticipants required chronic renal replacement therapy. Thus,
the final sample used in this study included 915 outpatient
adults. The local Ethics Committee approved the study
protocol.
Venous blood was collected from all participants in the
morning following an overnight fast. Serum glucose and
lipids were measured using enzymatic procedures with a
Roche/Hitachi Modular System P (Roche Diagnostics GmbH,
Milan, Italy), according to the manufacturer’s specifications
and employing proprietary reagents. Low-density lipoprotein
(LDL)-cholesterol was calculated with the Friedewald for-
mula. Serum creatinine was measured using a Roche/Hitachi
Modular System P with a Jaffe` rate blanked and compen-
sated assay. The calibrators for the Roche method were
traceable to an isotope dilution mass spectrometric method
for serum creatinine using standard reference methods.
Serum thyrotropin (TSH) concentrations were measured
with a third generation immunometric assay (functional sen-
sitivity of 0.01–0.02 mIU/L with an inter-assay imprecision
of ;20%) using the IMMULITE-2000 analyzer (Diagnostic
Products Corporation, Los Angeles, CA, USA). Serum con-
centrations of FT4 (by a solid-phase, chemiluminescent,
competitive analog immunoassay with a total imprecision of
-9.0%), anti-thyroglobulin (anti-TG) and anti-thyroperoxi-
dase (anti-TPO) antibodies (total imprecision of -5.6% and
-7.0% for anti-TG and anti-TPO, respectively) were also
measured with the IMMULITE-2000 analyzer. The reference
range for TSH was 0.35–4.0 mIU/L, for FT4 10–24 pmol/L, for
anti-TG antibody -40 IU/mL and for anti-TPO antibody
-35 IU/mL. Subclinical primary hypothyroidism was defined
as a serum TSH concentrations )4.0 mIU/L with normal FT4
values. Thyroid autoimmunity was defined as increased
titers of serum anti-TPO ()35 IU/mL) or anti-TG ()40 IU/mL)
antibodies.
eGFR was estimated using the abbreviated modification of
diet in renal disease (MDRD) equation (10) as follows:
eGFRs175=(serum creatinine–1.154)=(age–0.203)=1.212 (if
black)=0.742 (if female). For this study, CKD was defined as
an eGFR -60 mL/min/1.73 m2 (10).
Statistical analysis
Results are expressed as means"SD or proportions. Partic-
ipants were stratified into three categories based on the
eGFR (i.e., -60, 60–89 and G90 mL/min/1.73 m2). In these
analyses, we combined subjects with eGFR -45 mL/min/
1.73 m2 and those with eGFR 45–60 mL/min/1.73 m2 into a
single eGFR category due to the low number of individuals
with eGFR -45 mL/min/1.73 m2 (ns16). Skewed variables
(triglycerides, TSH, anti-TG and anti-TPO) were logarithmi-
cally transformed to achieve normality prior to analysis. Sta-
tistical analyses included the one-way analysis of variance
(for continuous variables) and the x2-test with Yates’s cor-
rection for continuity (for categorical measures). The joint
effects of an increased TSH concentration and thyroid auto-
immunity on eGFR values (included as a continuous meas-
ure) were tested using a 2-factor analysis of variance.
Moreover, the independence of associations between thy-
roid function test results and eGFR was tested by analysis of
covariance or multivariate logistic regression analysis.
Adjusting variables were age, gender, serum fasting glucose
and lipids. p-Values -0.05 were considered statistically
significant.
Results
After excluding subjects (ns85) with abnormal serum
FT4 concentrations wi.e., those with FT4 below
10 pmol/L (ns18) or above 24 pmol/L (ns67)x, cumu-
lative results for main demographic variables, serum
creatinine and thyroid function tests were retrieved
for 915 adult outpatients with a mean age of
48.9"15 years. There were 602 women and 313 men.
The mean eGFR was 89.6"22 mL/min/1.73 m2 (range:
31–202 mL/min/1.73 m2). Mean serum TSH and FT4
concentrations were 2.26"2.98 mIU/L (range: -0.001–
41.7 mIU/L) and 16.8"2.8 pmol/L (range: 10–24
pmol/L), respectively.
Most participants (ns729, 79.7%) had serum TSH
concentrations ranging from 0.35 mIU/L to 4.0 mIU/L.
10.7% (ns98) had subclinical biochemical hypothy-
roidism (i.e., TSH )4.0 mIU/L), and 9.6% (ns88) had
subclinical biochemical hyperthyroidism (i.e., TSH
-0.35 mIU/L). An increased anti-TPO antibody con-
centration was present in 172 (18.8%) subjects,
whereas an increased anti-TG antibody concentration
was present in 125 (13.7%).
Most participants (ns862, 94.2%) had an eGFR
)60 mL/min/1.73 m2, while 427 had an eGFRG90 mL/
min/1.73 m2. Fifty three (5.8% of total) subjects had an
eGFR -60 mL/min/1.73 m2. Of these, 37 of had an
eGFR between 45 mL/min/1.73 m2 and 59 mL/min/
1.73 m2 and 16 had an eGFR -45 mL/min/1.73 m2.
Baseline characteristics of the participants accord-
ing to eGFR categories are shown in Table 1. Partici-
pants with lower eGFR were older, more likely to be
female and had significantly higher serum concentra-
tions of TSH and anti-thyroid antibodies compared
with those showing normal or near-normal kidney
function. The prevalence of participants with serum
TSH concentrations )4.0 mUI/L or with increased
titers of serum anti-thyroid antibodies steadily
increased among persons with progressively lower
eGFR values (ranging from 7.7% to 26.4% for TSH,
from 15.4% to 28.3% for anti-TPO antibody, and from
10.2% to 26.4% for anti-TG antibody). The prevalence
of increased anti-TPO and/or anti-TG antibodies
ranged from 18.7% to 34.0% across eGFR categories
(Table 1). Serum triglycerides tended to be higher,
and high density lipoprotein (HDL)-cholesterol tended
to be lower among persons with progressively lower
eGFR values, but these did not reach statistical sig-
nificance. Serum concentrations of FT4 and fasting
glucose were not significantly different among eGFR
categories. Notably, as also shown in Table 1, the sig-
nificant differences in TSH and anti-thyroid antibod-
ies, observed across eGFR categories, remained
unchanged even after adjusting for age and gender.
Additional adjustment for fasting plasma glucose and
lipid parameters did not materially alter the results
(data not shown).
Conversely, compared with participants without
hypothyroidism (ns817), those with subclinical hypo-
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Table 1 Clinical and biochemical characteristics of participants stratified according to eGFR.
-60 60–89 G90 Unadjusted Age- and sex-
mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 p-values adjusted
p-valuesa
Gender (male/female) 10/43 120/315 183/244 -0.0001 –
Age, years 66"16 53"13 43"14 -0.0001 –
FT4, pmol/L 16.5"3.2 16.7"2.6 16.8"2.8 0.71 0.54
Thyrotropin, mUI/L 3.43"4.1 2.41"3.5 1.94"2.1 -0.001 -0.001
Anti-TPO antibody, IU/mL 510"2741 142"584 96"402 0.0024 0.01
Anti-TG antibody, IU/mL 1462"8250 130"983 47"240 -0.001 0.01
Thyrotropin )4 mUI/L, % 26.4% 11.7% 7.7% -0.001 -0.001
Anti-TPO antibodies )35 IU/mL, % 28.3% 20.9% 15.4% -0.01 0.02
Anti-TG antibodies )40 IU/mL, % 26.4% 15.4% 10.2% 0.0019 0.01
Increased anti-TPO and/or anti-TG 34.0% 26.4% 18.7% 0.004 0.01
antibodies, %
Fasting glucose, mmol/L 5.12"1.1 5.11"1.0 5.17"1.1 0.61 ND
Triglycerides, mmol/L 1.36"0.65 1.32"0.65 1.18"0.80 0.07 ND
HDL-cholesterol, mmol/L 1.50"0.41 1.59"0.43 1.60"0.39 0.11 ND
LDL-cholesterol, mmol/L 3.39"0.64 3.24"0.89 3.22"0.85 0.72 ND
eGFR, mL/min/1.73 m2 49"9 77"8 107"18 ND ND
Cohort sizes915. Data are expressed as means"SD or proportions. Unadjusted p-values for trends by the one-way analysis
of variance (for continuous variables) or the x2-test (for categorical variables). aAdjusted p-values for trends by the analysis
of covariance (for continuous variables) or the logistic regression analysis (for categorical measures). eGFR, estimated glom-
erular filtration rate; FT4, free thyroxine; anti-TPO, anti-thyroperoxidase; anti-TG, anti-thyroglobulin; ND, not determined; HDL,
high-density lipoprotein; LDL, low-density lipoprotein.
Figure 1 Age-adjusted prevalence of chronic kidney dis-
ease, as defined as estimated glomerular filtration rate
-60 mL/min/1.73 m2, by concentrations of serum thyrotro-
pin and anti-thyroid antibodies.
Figure 2 Joint effects of increased serum thyrotropin (TSH)
concentrations and thyroid autoimmunity (defined as ele-
vated anti-TPO and/or anti-TG antibodies) on estimated
glomerular filtration rate values (ns915).
Data are adjusted for age and gender.
thyroidism (ns98) were slightly older, less likely to
be male and had slightly higher LDL-cholesterol, and
lower eGFR values (81.1"22 vs. 91.2"22 mL/min/
1.73 m2; p-0.0001). As shown in Figure 1, they also
had a greater age-adjusted prevalence of individuals
with CKD (i.e., eGFR -60 mL/min/1.73 m2). Moreover,
as expected, there was a much higher proportion of
individuals with increased serum anti-TPO (43.9% vs.
15.8%, p-0.0001) or anti-TG antibodies (33.7% vs.
11.3%, p-0.0001) in the hypothyroid subgroup. Sim-
ilarly, compared with participants with no thyroid
autoimmunity (ns702), those with increased levels of
anti-TPO and/or anti-TG (ns213) had a greater age-
adjusted prevalence of individuals with CKD (Figure
1).
Figure 2 shows the joint effects of TSH and thyroid
autoimmunity on age-, and gender-adjusted values of
eGFR. In this analysis, we found that a serum TSH
)4.0 mUI/L and increased titers of anti-thyroid anti-
bodies exerted an additive effect on mean eGFR val-
ues (Figure 2). However, decreasing eGFR values
appeared to be more strongly related with the
increase in TSH, rather than with thyroid autoimmun-
ity (p-0.001 for TSH, ps0.12 for thyroid autoimmun-
ity, and ps0.62 for the interaction term). Essentially
identical results were found when eGFR was included
as categorical measure (eGFR F60 vs. )60 mL/min/
1.73 m2) (data not shown).
Discussion
From a clinical practice viewpoint, it should be men-
tioned that clinically overt thyroid dysfunction, espe-
cially overt hypothyroidism, is accompanied by
significant changes in renal blood flow, glomerular
and tubular function, and electrolyte and water
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homeostasis. Conversely, a marked decline in kidney
function is accompanied by changes in the synthesis,
secretion, metabolism, and elimination of thyroid
hormones (1, 2).
To our knowledge, at present there is no informa-
tion available regarding the epidemiology of thyroid
autoimmunity in individuals, including large non-US
cohort with different levels of eGFR.
Lo et al. (4) recently reported that the prevalence of
subclinical and clinical hypothyroidism in US adults
was ;24% among persons with an eGFR -60
mL/min/1.73 m2. Their study differed from ours in that
their multi-ethnic US cohort had a greater prevalence
of males, only 56% of hypothyroid cases were consid-
ered subclinical, and serum FT4 concentrations were
not measured. Moreover, no information was availa-
ble on the prevalence of thyroid autoimmunity in
those with CKD.
In a recent study (5), we demonstrated in a large
sample of unselected outpatients who presented to
our laboratory between December 2005 and Decem-
ber 2007, the prevalence of subclinical primary hypo-
thyroidism was ;20% among persons with CKD.
However, since no information was available on
serum anti-thyroid antibodies in this study (5), we
were unable to investigate the prevalence of thyroid
autoimmunity and the effects of increased TSH con-
centrations and thyroid autoimmunity on eGFR
values.
The major finding of our study is that there is a high
frequency of thyroid autoimmunity (34%) and subclin-
ical primary hypothyroidism (26.4%) in persons with
an eGFR -60 mL/min/1.73 m2. Notably, this finding
was observed in a cohort of adult outpatients, and did
not include subjects with abnormal serum FT4 con-
centrations or with CKD requiring chronic dialysis.
The evaluation of subjects with such complications
would almost certainly have confounded interpreta-
tion of the data. For example, it is known that in
patients with renal failure it is not unusual to observe
the low triiodothyronine (T3) syndrome; a common
condition characterized by alterations in thyroid func-
tion likely due to non-thyroidal illness causes (11). In
patients with renal failure, low serum free T3 concen-
trations are independently associated with increased
risk of all-cause mortality (12, 13). Finally, as expected
(10, 14), we also found that participants with lower
eGFR were significantly older than those with normal
or near-normal kidney function. Moreover, they also
tended to have higher triglycerides and lower HDL-
cholesterol concentrations. However, fasting glucose
and LDL-cholesterol concentrations did not differ sig-
nificantly among eGFR categories. We believe that the
lack of information on the use of lipid-lowering drugs
did not allow us to observe a stronger statistical asso-
ciation between atherogenic dyslipidemia (i.e., high
triglycerides and low HDL-cholesterol) and decreased
kidney function. It is known that CKD patients have a
greater prevalence of atherogenic dyslipidemia than
those without CKD (14, 15).
Our study has several important limitations that
merit comment. First, the cross-sectional design of
the study precludes the establishment of causal or
temporal relationships between thyroid autoimmuni-
ty, subclinical hypothyroidism and kidney disease. In
particular, although our results were adjusted for age,
it is known that the prevalence of CKD, thyroid auto-
immunity and TSH concentrations increase markedly
with age (14, 16). Thus, future prospective studies are
needed to clarify these issues. Second, since our anal-
ysis depended on the use of automated databases to
establish the presence of subclinical primary hypothy-
roidism and kidney disease, it may have led to some
misclassification. In particular, we did not have any
information on the causes of kidney disease, coexist-
ing medical conditions and current use of medica-
tions, including thyroid replacement therapy or
anti-thyroid drugs. In addition, although we evaluated
the most common cause of subclinical primary hypo-
thyroidism (i.e., chronic autoimmune thyroiditis, typ-
ically characterized by increased levels of anti-thyroid
antibodies), no information was available on other
less common causes of transient or permanent pri-
mary hypothyroidism, such as drug-induced hypothy-
roidism, subacute thyroiditis, radiation thyroiditis, or
post-partum thyroiditis (9). However, we believe that
the lack of these data does not detract from the novel
and interesting finding of the high prevalence of
thyroid autoimmunity among persons with reduced
eGFR. Third, thyroid function tests could be requested
when there was a clinical suspicion of altered thyroid
function, thus tending to inflate the magnitude of the
relationship. However, we excluded all patients with
low or high serum FT4 levels, who are likely to have
clinical symptoms of hypothyroidism or hyperthyroid-
ism, respectively. Finally, we used an eGFR instead of
a directly measured GFR to define CKD. It is known
that current GFR equations have limited precision and
systematically underestimate measured GFR at high-
er values (i.e., in populations without known CKD).
However, current GFR equations facilitate the detec-
tion, evaluation, and management of CKD, and many
organizations recommend the use of equations that
estimate GFR for the evaluation of kidney function in
large epidemiological studies and in clinical practice
(10).
Despite these limitations, this analysis has several
important strengths. First, as reported above, we
excluded patients who required chronic dialysis and
those who had overt thyroid dysfunction. Second, our
clinical laboratory used uniform methods to collect
data on thyroid function test results. Third, the avail-
ability of complete data on important risk factors,
including age, gender, plasma glucose and the lipid
profile, allowed us to provide an unbiased estimate
for the relationship between subclinical hypothyroid-
ism, thyroid autoimmunity and kidney disease. Final-
ly, we evaluated a large sample, and found a strong,
graded, relationship between eGFR and thyroid func-
tion tests, even within the reference intervals.
In conclusion, our findings suggest that there is a
high prevalence of thyroid autoimmunity and subclin-
ical primary hypothyroidism in a large non-US out-
patient cohort of persons with CKD not requiring
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chronic dialysis. Further experimental and prospec-
tive studies are needed to confirm these findings and
to elucidate the underlying biologic mechanisms
before causality can be firmly established.
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